中美药品监管体制比较研究：一个经济学的视角的中期报告摘要：本研究旨在比较中美药品监管体制，从经济学的视角探究两国监管体制的优缺点，并提出一些政策建议。本研究发现，中美两国药品监管体制有许多相似之处，但也存在显著的差异。美国的药品监管体制基于法律和法规，具有高度的透明度和公正性，但存在监管成本高、审批时间长等问题。相比之下，中国的药品监管体制更加集中和权威，但存在着信息不对称、政府干预较多等问题。本研究提出，两国应从战略高度加强监管合作，共同制定全球公认的药品监管标准，并提高监管的效率和透明度。此外，可以通过加强对社会的监管宣传和加大监管力度来提高公众的监管意识和信任度。关键词：药品监管，中美比较，经济学视角，政策建议Abstract:ThisstudyaimstocomparethedrugregulatorysystemsofChinaandtheUnitedStates,exploretheadvantagesanddisadvantagesofthetworegulatorysystemsfromaneconomicperspective,andputforwardsomepolicyrecommendations.ThestudyfoundthattherearemanysimilaritiesbetweenthedrugregulatorysystemsofChinaandtheUnitedStates,buttherearealsosignificantdifferences.TheUSdrugregulatorysystemisbasedonlawsandregulations,andhasahighdegreeoftransparencyandfairness,butthereareproblemssuchashighregulatorycostsandlongapprovaltimes.Incontrast,China'sdrugregulatorysystemismorecentralizedandauthoritativebutthereareproblemssuchasinformationasymmetryandexcessiveinterventionofthegovernment.Thestudyproposesthatthetwocountriesshouldstrengthenregulatorycooperationfromastrategicheight,jointlyformulategloballyrecognizeddrugregulatorystandards,andimprovetheefficiencyandtransparencyofregulation.Inaddition,improvingpublicawarenessandtrustinregulationcanbeachievedbystrengtheningregulatorypublicityandincreasingregulatoryefforts.Keywords:drugregulation,China-UScomparison,economicperspective,policyrecommendations